Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PHASE 2 INTERVENTIONAL STUDY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY IN PARTICIPANTS WITH PREVIOUSLY UNTREATED TRANSFORMED SMALL CELL LUNG CANCER

NCT07476287 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT07476287
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07476287 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PHASE 2 INTERVENTIONAL STUDY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY IN PARTICIPANTS WITH PREVIOUSLY UNTREATED TRANSFORMED SMALL CELL LUNG CANCER
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Recruiting
Start date
July 2, 2026
Completion date
March 24, 2031
Enrollment
40 (estimated)
Sites
61

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, small cell lung, lung neoplasms, small cell cancer of the lung, small cell lung cancer, small cell lung cancer ( sclc ), transformed small cell lung cancer